




Searching News Database: amlodipine
HSMN NewsFeed - 29 Jan 2016
Viacoram(R) now approved in Canada as a new first line treatment in hypertension
Viacoram(R) now approved in Canada as a new first line treatment in hypertension
HSMN NewsFeed - 26 Jul 2010
FDA Approves Tribenzor, A New Three-In-One Combination Product for the Treatment of High Blood Pressure
FDA Approves Tribenzor, A New Three-In-One Combination Product for the Treatment of High Blood Pressure
HSMN NewsFeed - 13 May 2009
AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure
AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure
HSMN NewsFeed - 28 Jan 2009
Ipsen announces the signature of a co-promotion agreement with Novartis for Exforge in France
Ipsen announces the signature of a co-promotion agreement with Novartis for Exforge in France
HSMN NewsFeed - 27 Feb 2008
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
HSMN NewsFeed - 18 Dec 2007
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
HSMN NewsFeed - 5 Dec 2007
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
HSMN NewsFeed - 2 Dec 2007
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
HSMN NewsFeed - 21 Aug 2007
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
HSMN NewsFeed - 16 Jul 2007
CV Therapeutics Names Lewis Stuart Senior Vice President, Commercial Operations
CV Therapeutics Names Lewis Stuart Senior Vice President, Commercial Operations
HSMN NewsFeed - 10 Jul 2007
Ranbaxy Receives Final Approval To Manufacture and Market Amlodipine Besylate Tablets
Ranbaxy Receives Final Approval To Manufacture and Market Amlodipine Besylate Tablets
HSMN NewsFeed - 20 Jun 2007
Ranbaxy Receives Tentative Approval to Manufacture and Market Amlodipine Besylate Tablets
Ranbaxy Receives Tentative Approval to Manufacture and Market Amlodipine Besylate Tablets
HSMN NewsFeed - 24 Apr 2007
Journal of the American Medical Association Publishes MERLIN TIMI-36 Results
Journal of the American Medical Association Publishes MERLIN TIMI-36 Results
HSMN NewsFeed - 18 Apr 2007
FDA Confirms Mylan's Status as the Only Approved ANDA for all Strengths of Amlodipine Besylate Tablets
FDA Confirms Mylan's Status as the Only Approved ANDA for all Strengths of Amlodipine Besylate Tablets
HSMN NewsFeed - 27 Mar 2007
U.S. District Court Enjoins the FDA from Approving Additional Amlodipine Besylate ANDAs
U.S. District Court Enjoins the FDA from Approving Additional Amlodipine Besylate ANDAs
HSMN NewsFeed - 23 Mar 2007
Pfizer Announces Launch of Generic Amlodipine Besylate Product by Greenstone
Pfizer Announces Launch of Generic Amlodipine Besylate Product by Greenstone
HSMN NewsFeed - 22 Mar 2007
Pfizer Statement in Response to Appeals Court Decision in Norvasc Patent Case
Pfizer Statement in Response to Appeals Court Decision in Norvasc Patent Case
HSMN NewsFeed - 14 Mar 2007
JACC Publishes Long-Term Safety and Tolerability Data from Ranolazine Open Label Experience (ROLE) Program
JACC Publishes Long-Term Safety and Tolerability Data from Ranolazine Open Label Experience (ROLE) Program
HSMN NewsFeed - 31 Jan 2007
Court Rules In Pfizer's Favor In Norvasc Patent Case, Finds Synthon Obtained Patent By Inequitable Conduct
Court Rules In Pfizer's Favor In Norvasc Patent Case, Finds Synthon Obtained Patent By Inequitable Conduct
HSMN NewsFeed - 4 Dec 2006
Risk of Heart Attack Significantly Reduced in About 90 days by Modern Combination of Drugs
Risk of Heart Attack Significantly Reduced in About 90 days by Modern Combination of Drugs
HSMN NewsFeed - 26 Oct 2006
CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2006
CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2006
HSMN NewsFeed - 11 Oct 2006
CV Therapeutics Ending Co-Promotion of ACEON(R) (perindopril erbumine) Tablets
CV Therapeutics Ending Co-Promotion of ACEON(R) (perindopril erbumine) Tablets
HSMN NewsFeed - 13 Jul 2006
Mylan Announces Tentative Approval for Amlodipine Besylate and Benazepril Hydrochloride Capsules
Mylan Announces Tentative Approval for Amlodipine Besylate and Benazepril Hydrochloride Capsules
HSMN NewsFeed - 9 May 2006
Angina Patients Cost Managed Care Over Twice as Much as Coronary Artery Disease Patients Without Angina
Angina Patients Cost Managed Care Over Twice as Much as Coronary Artery Disease Patients Without Angina
Additional items found! 42

Members Archive contains
42 additional stories matching:
amlodipine
(Password required)
amlodipine
(Password required)